BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31656672)

  • 1. Alpha-l-fucosidase: a novel serum biomarker to predict prognosis in early stage esophageal squamous cell carcinoma.
    Yu X; Zhang R; Yang T; Zhang M; Xi K; Lin Y; Wen Y; Wang G; Huang Z; Zhang X; Zhang L
    J Thorac Dis; 2019 Sep; 11(9):3980-3990. PubMed ID: 31656672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preoperative serum α-1-fucosidase as an early-recurrent indicator for hepatocellular carcinoma following curative resection].
    Zhou Y; Ma X; Wu J; Zhang C; Wang B; Song B; Guo W; Pan B
    Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(46):3623-8. PubMed ID: 25622951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-1-fucosidase as a prognostic indicator for hepatocellular carcinoma following hepatectomy: a large-scale, long-term study.
    Wang K; Guo W; Li N; Shi J; Zhang C; Lau WY; Wu M; Cheng S
    Br J Cancer; 2014 Apr; 110(7):1811-9. PubMed ID: 24569461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase (AFU) as novel diagnostic biomarkers for hepatocellular carcinoma.
    Mossad NA; Mahmoud EH; Osman EA; Mahmoud SH; Shousha HI
    Tumour Biol; 2014 Nov; 35(11):11559-64. PubMed ID: 25129443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-L-Fucosidase Serves as a Prognostic Indicator for Intrahepatic Cholangiocarcinoma and Inhibits Its Invasion Capacity.
    Shuang Z; Mao Y; Lin G; Wang J; Huang X; Chen J; Duan F; Li S
    Biomed Res Int; 2018; 2018():8182575. PubMed ID: 29682557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative AFU Is a Useful Serological Prognostic Predictor for Colorectal Liver Oligometastasis Patients Undergoing Hepatic Resection.
    Deng Y; Zhao Y; Fan W; Peng J; Luo X; Mo Y; Xiao B; Zhang L; Pan Z
    J Cancer; 2019; 10(21):5049-5056. PubMed ID: 31602256
    [No Abstract]   [Full Text] [Related]  

  • 7. Rapid kinetic rate assay of the serum alpha-L-fucosidase in patients with hepatocellular carcinoma by using a novel substrate.
    Wang JJ; Cao EH
    Clin Chim Acta; 2004 Sep; 347(1-2):103-9. PubMed ID: 15313147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: Cross-sectional study.
    Lu ZY; Cen C; Shao Z; Chen XH; Xu CF; Li YM
    World J Gastroenterol; 2016 Feb; 22(5):1884-90. PubMed ID: 26855548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum AFU, 5'-NT and AFP as Biomarkers for Primary Hepatocellular Carcinoma Diagnosis.
    Junna Z; Gongde C; Jinying X; Xiu Z
    Open Med (Wars); 2017; 12():354-358. PubMed ID: 29043300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma.
    Fawzy Montaser M; Amin Sakr M; Omar Khalifa M
    Arab J Gastroenterol; 2012 Mar; 13(1):9-13. PubMed ID: 22560818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study.
    Liu D; Luo Y; Chen L; Chen L; Zuo D; Li Y; Zhang X; Wu J; Xi Q; Li G; Qi L; Yue X; Zhang X; Sun Z; Zhang N; Song T; Lu W; Guo H
    Cancer Biol Med; 2021 Feb; 18(1):256-270. PubMed ID: 33628599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of pretreatment serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ratio and gamma glutamyltransferase (GGT) in patients with esophageal squamous cell carcinoma.
    Huang H; Wang XP; Li XH; Chen H; Zheng X; Lin JH; Kang T; Zhang L; Chen PS
    BMC Cancer; 2017 Aug; 17(1):544. PubMed ID: 28806937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association and prognostic significance of alpha-L-fucosidase-1 and matrix metalloproteinase 9 expression in esophageal squamous cell carcinoma.
    Yu XY; Lin SC; Zhang MQ; Guo XT; Ma K; Wang LX; Huang WT; Wang Z; Yu X; Wang CG; Zhang LJ; Yu ZT
    World J Gastrointest Oncol; 2022 Feb; 14(2):498-510. PubMed ID: 35317318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-L-fucosidase levels in patients with oral submucous fibrosis and controls: A comparative study.
    Suresh H; Gunasekaran N; James A; Krishnan R; Thayalan DK; Kumar AR
    J Oral Maxillofac Pathol; 2022; 26(4):594. PubMed ID: 37082061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of serum γ-glutamyl transferase isoenzyme II, α-L-fucosidase and α-fetoprotein detected using a commercial kit in the diagnosis of hepatocellular carcinoma.
    Zhu J; Jiang F; Ni HB; Xiao MB; Chen BY; Ni WK; Lu CH; Ni RZ
    Exp Ther Med; 2013 Jan; 5(1):89-94. PubMed ID: 23251247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of α-L-fucosidase for early detection of hepatocellular carcinoma.
    Xing H; Qiu H; Ding X; Han J; Li Z; Wu H; Yan C; Li H; Han R; Zhang H; Li C; Wang M; Wu M; Shen F; Zheng Y; Yang T
    Biomark Med; 2019 May; 13(7):545-555. PubMed ID: 31140827
    [No Abstract]   [Full Text] [Related]  

  • 17. The Applicability of ADA, AFU, and LAC in the Early Diagnosis and Disease Risk Assessment of Hepatitis B-Associated Liver Cirrhosis and Hepatocellular Carcinoma.
    Zhang W; Chen Z; Xue C; Zhang Y; Wu L; Zhu J; Xuan S; Tian J; Pang Z
    Front Med (Lausanne); 2021; 8():740029. PubMed ID: 34557505
    [No Abstract]   [Full Text] [Related]  

  • 18. Alpha-L-fucosidase as a serum marker of hepatocellular carcinoma in Thailand.
    Tangkijvanich P; Tosukhowong P; Bunyongyod P; Lertmaharit S; Hanvivatvong O; Kullavanijaya P; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 1999 Mar; 30(1):110-4. PubMed ID: 10695798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The value of serum alpha-L-fucosidase activity in the diagnosis of primary liver cancer].
    Wei X; Wang S; Rui J
    Zhonghua Zhong Liu Za Zhi; 2000 Mar; 22(2):148-50. PubMed ID: 11776645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative serum alpha-L-fucosidase activity as a prognostic marker in colorectal cancer.
    Ayude D; Páez De La Cadena M; Martínez-Zorzano VS; Fernández-Briera A; Rodríguez-Berrocal FJ
    Oncology; 2003; 64(1):36-45. PubMed ID: 12457030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.